| Name of the Instrument/Tool | Central Sensitization Inventory (CSI) |
| First Description |
Mayer TG, Neblett R, Cohen H, et al. The development and psychometric validation of the central sensitization inventory. Pain Practice 2012; 12(4):276-285. |
| Year | 2012 |
| Domains | |
| Concept of constructs | Pain |
| Population/Disease | Generic |
| Originally developed for | --- |
| Other rheumatic diseases where can be applied (only if validated) |
Fibromyalgia (FM), Osteoarthritis (OA), Chronic musculoskeletal pain |
| Additional population with no rheumatic diseases |
No |
| Language: Originally published in | English |
| Available in Language | Danish, Portuguese, Russian, Greek, French, Spanish, Dutch, Polish, English, Swedish |
| REFERENCE IDENTIFICATION | |
| Author/s | Mayer TG, Neblett R, Cohen H, Howard KJ, Choi YH, Williams MJ, Perez Y, Gatchel RJ. |
| Title | The development and psychometric validation of the central sensitization inventory. |
| Journal | Pain Practice |
| Year | 2012 |
| Vol | 12 |
| Num | (4): |
| Pages | 276-285 |
| Country | United States of America |
| Language | English |
| Other references of interest | |
| Link | https://pubmed.ncbi.nlm.nih.gov/35754083/ |
| Brief Description |
Validity of the Central Sensitization Inventory (CSI) through Rasch analysis in patients with knee osteoarthritis. |
| Link | https://onlinelibrary.wiley.com/doi/abs/10.1111/jabr.12123 |
| Brief Description |
This article provides an overview of CSI rationale, development, recommended uses, and research results, including evidence of validity and reliability, in clinical and non-clinical subject samples. |
| Link | https://www.ncbi.nlm.nih.gov/pubmed/28851012 |
| Brief Description |
SLR with the objective to determine the quality of evidence these publications reported, and examine the measurement properties of the CSI. |
| Instrument/Tool Translations References | |
| Link | https://www.ncbi.nlm.nih.gov/pubmed/27818875 |
| Brief Description |
Cross-cultural adaptation and validity of the Spanish central sensitization inventory. |
| Link | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589103/ |
| Brief Description |
Assessment of the psychometric properties of the CSI, adapted and validated for a Brazilian population (CSI-BP). |
| Link | https://www.ncbi.nlm.nih.gov/pubmed/22035625 |
| Brief Description |
A systematic literature review (SLR) addressing central sensitization and central nociceptive processing in patients with rheumatoid arthritis (RA). https://pubmed.ncbi.nlm.nih.gov/36097821/ Salaffi F, Farah S, Mariani C, Sarzi-Puttini P, Di Carlo M. Validity of the Central Sensitization Inventory compared with traditional measures of disease severity in fibromyalgia. Pain Pract. 2022 Nov;22(8):702-710. doi: 10.1111/papr.13162. Epub 2022 Sep 22. PMID: 36097821; PMCID: PMC9826291. |
| DEVELOPER CONTACT INFORMATION | |
| Correspondence to | Robert J. Gatchel, PhD, |
| gatchel@uta.edu | |
| Address | Department of Psychology, College of Science, The University of Texas at Arlington, 5701 Maple Ave. no. 100, Dallas, TX 75235, U.S.A. |
| Website | --- |
| Available | --- |
| Links | --- |
| DESCRIPTION OF THE INSTRUMENT | |
| Type Of Measure | Questionnaire |
| Brief Description |
The Central Sensitization Inventory (CSI) may be used to determine severity of central sensitization pain. The CSI has two parts, Part A and Part B. For scoring purposes you will only look at the 25 questions in Part A. Part B was initially used to help correlate the results with previous diagnoses. |
| Number of Items | 25 |
| Range | 0-100 |
| Responses options/scale |
Yes 5 |
| Developed for | Both |
| PRACTICAL APPLICATION | |
| Method of administration | Self-administered |
| Recommendations to score |
Each question may be answered as follows: Never (0 points), Rarely (1 point), Sometimes (2 points), Often (3 points), or Always (4 points). |
| Score Interpretation | Total points reflect the severity of central sensitization pain. |
| Cut-off points | Score ranges and the intensity of CSP they represent are: Subclinical: 0 to 29 Mild: 30 to 39 Moderate: 40 to 49 Severe: 50 to 59 Extreme: 60 to 100 |
| Cut-off points applied to | Not specified |
| Smallest detectable change if described | --- |
| Smallest detectable change applied to | --- |
| Completion time by the patient | 5 minutes |
| Scoring time by the assessor | - minutes |
| Training to score | Not necessary |
| Strengths | Useful in clinical practice & research, Easy to use |
| Limitations | --- |
| OTHER COMMENTS | |
| Other Comments |
|